Table 3.
Percentage of the abnormalities of the levels of the routine inflammatory markers of SARS-CoV-2, sCD25, and sCD163 in patients with SARS-CoV-2
| Laboratory markers | All patients with SARS-CoV-2 (n = 29) | Patients with COVID-19 (n = 13) | Patients with MIS-C (n = 16) |
|---|---|---|---|
| Lymphopenia | 14/29 (48.28%) | 5/13 (38.46%) | 9/16 (56.25%) |
| Neutrophilia | 15/29 (51.72%) | 5/13 (38.46%) | 10/16 (62.25%) |
| Neutropenia | 1/29 (3.45%) | 1/13 (7.69%) | 0.0% |
| Thrombocytopenia | 10/29 (34.48%) | 3/13 (23.08%) | 7/16 (43.75%) |
| Elevated CRP | 26/29 (89.66%) | 11/13 (84.62%) | 15/16 (93.75%) |
| Elevated ferritin | 19/29 (65.52%) | 5/13 (38.46%) | 14/16 (87.50%) |
| Elevated ALT | 7/29 (24.14%) | 1/13 (7.69%) | 6/16 (37.5%) |
| Elevated LDH | 22/29 (75.86%) | 11/13 (84.62%) | 11/16 (68.75%) |
| Elevated D-dimer | 27/29 (93.10%) | 11/13 (84.62%) | 100% |
| Elevated ESR | 12/29 (41.38%) | 7/13 (53.85%) | 5/16 (31.25%) |
| Elevated sCD25 | 100% | 100% | 100% |
| Elevated sCD163 | 100% | 100% | 100% |
ALT alanine transaminase; COVID-19 coronavirus disease 2019; CRP C-reactive protein; ESR erythrocyte sedimentation rate; LDH lactate dehydrogenase; MIS-C multisystem inflammatory syndrome in children; SARS-CoV-2 severe acute respiratory syndrome coronavirus-2